Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: Use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation

European Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 39-42

  Esteve M A ^a   Devictor Pierre, B ^a   Galy, G ^a   Andre N ^a   Coze, C ^a   Lacarelle, B ^a   Bernard, J L ^a   Monjanel Mouterde, S ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE G2; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ACUTE TOXICITY; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CONTINUOUS INFUSION; CONVALESCENCE; CONVULSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG MONITORING; EDEMA; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENERAL CONDITION DETERIORATION; HEALTH STATUS; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; RETREATMENT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VALIDATION PROCESS; VISUAL DISORDER;

ADOLESCENT; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; DRUG MONITORING; FEMALE; GAMMA-GLUTAMYL HYDROLASE; HUMANS; METHOTREXATE; OSTEOSARCOMA;

EID: 33845899396     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0212-1     Document Type: Article

References (22)

1. Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G et al (2005) Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 92:480-487
2. Camitta BM, Holcenberg JS (1978) Safety of delayed leucovorin "rescue" following high-dose methotrexate in children. Med Pediatr Oncol 5:55-59
3. Canal P, Gamelin E, Vassal G, Robert J (1998) Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy. Pathol Oncol Res 4:171-178
4. Cano JP, Bruno R, Lena N, Favre R, Iliadis A, Imbert AM (1985) Dosage predictions in high-dose methotrexate infusions. Part 1: evaluation of the classic test-dose protocol. Cancer Drug Deliv 2:271-276
5. Donehower RC, Hande KR, Drake JC, Chabner BA (1979) Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate. Clin Pharmacol Ther 26:63-72
6. Donehower RC (1980) Metabolic conversion of methotrexate in man. Recent Results Cancer Res 74:37-41
7. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR (1979) Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 3:161-166
8. Hempel L, Misselwitz J, Fleck C, Kentouche K, Leder C, Appenroth D et al (2003) Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 40:348-354
9. Huvos AG, Rosen G, Marcove RC (1977) Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101:14-18
10. Iliadis A, Brown AC, Huggins ML (1992) APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed 38:227-239
11. Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA (1983) Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther 33:44-51
12. Krause AS, Weihrauch MR, Bode U, Fleischhack G, Elter T, Heuer T et al (2002) Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphom 43:2139-2143
13. Minton NP, Atkinson T, Sherwood RF (1983) Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 156:1222-1227
14. Peyriere H, Cociglio M, Margueritte G, Vallat C, Blayac JP, Hillaire-Buys D (2004) Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother 38:422-427
15. Pignon T, Lacarelle B, Duffaud F, Guillet P, Catalin J, Durand A et al (1994) Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 33:420-424
16. Sand TE, Jacobsen S (1981) Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 19:453-456
17. United States Department of Health and Human Services, Food and Drug Administration (2001) Guidance for Industry Bioanalytical Method Validation
18. Vallée S, Monjanel-Mouterde S, Bagarry-Liegey D et al (2001) Adaptation individuelle de posologie du méthotrexate (MTX) chez un insuffisant rénal sévère: danger de la méthode bayésienne. J Pharm Clin 20:225-228
19. Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC (1995) Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 76:521-526
20. Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ, O'Brien M et al (1997) Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 15:2125-2134
21. Widemann BC, Sung E, Anderson L, Salzer WL, Balis FM, Monitjo KS et al (2000) Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther 294:894-901
22. Widemann B, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S et al (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100:2222-2232